JITC Digest – January 2016

Inside this Issue

From the Authors
"In this manuscript, [we discuss] the most recent updates regarding immunotherapy in hepatocellular carcinoma, kidney and bladder cancer," said Dr. Ascierto.

From the Authors
“With valuable input from a group of international experts in Working Group 2 of the SITC Immune Biomarkers Task Force, this white paper shares our current understanding of emerging biomarkers for immune checkpoint blockade therapies, optimizing strategies for translational biomarker research with novel technologies, and guiding future personalized combination cancer immunotherapies," said Dr. Yuan.

"We are also excited to present the key findings from the white paper and participate in panel discussions about the future of biomarker research at the Immunotherapy Biomarkers Meeting in April. The presentations from Working Group 2 will highlight these findings and cover topics including multispectral imagining, the tumor mutational landscape and clinical response to immunotherapy, defining new metrics of competence by CyTOF, and multifaceted immunomonitoring to identify predictive biomarkers in melanoma patients."

Short Reports

From the Author
"Protein microarrays allow us to understand the spectrum of autoantibody responses in patients before and after cancer immunotherapies," said Dr. Yuan. "It will be important to explore their correlation with clinical outcome as well as immune related adverse events in the future studies."

Get More on Biomarkers in Cancer Immunotherapy

Immunotherapy Biomarkers 2016: Overcoming the Barriers

Cosponsored with the National Cancer Institute

Friday, April 1, 2016 • 8 a.m. – 5 p.m.
National Institutes of Health Campus • Bethesda, Maryland

Organized by the SITC Immune Biomarkers Task Force in collaboration with the NCI Center for Cancer Research, this one-day scientific program will review the state of the art, explore current hurdles to further success, and consider recommendations to move the field forward.

Register Now